ADAM9 Expression is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer

European Urology

Volumn 54, Issue 5, 2008, Pages 1097-1108

  Fritzsche, Florian R ^a   Jung, Monika ^a   Tölle, Angelika ^a   Wild, Peter ^b   Hartmann, Arndt ^c   Wassermann, Kirsten ^a   Rabien, Anja ^a   Lein, Michael ^a   Dietel, Manfred ^a   Pilarsky, Christian ^d   Calvano, Daniela ^d   Grützmann, Robert ^d   Jung, Klaus ^a   Kristiansen, Glen ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

ADAM9; Immunohistochemistry; Prognostic marker; Prostate cancer; qRT PCR

Indexed keywords

ADAM PROTEIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN ADAM9; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADAM PROTEINS; AGED; BLOTTING, WESTERN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 55649111365     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.11.034     Document Type: Article

References (30)

1. Nath D., Slocombe P.M., Webster A., et al. Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta(1)integrin, leading to a marked induction of fibroblast cell motility. J Cell Sci 113 pt 12 (2000) 2319-2328
2. Iba K., Albrechtsen R., Gilpin B.J., Loechel F., and Wewer U.M. Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am J Pathol 154 (1999) 1489-1501
3. Schwettmann L., and Tschesche H. Cloning and expression in Pichia pastoris of metalloprotease domain of ADAM 9 catalytically active against fibronectin. Protein Expr Purif 21 (2001) 65-70
4. Zhou M., Graham R., Russell G., and Croucher P.I. MDC-9 (ADAM-9/Meltrin gamma) functions as an adhesion molecule by binding the alpha(v)beta(5) integrin. Biochem Biophys Res Commun 280 (2001) 574-580
5. Lendeckel U., Kohl J., Arndt M., et al. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 131 (2005) 41-48
6. Izumi Y., Hirata M., Hasuwa H., et al. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 17 (1998) 7260-7272
7. Roghani M., Becherer J.D., Moss M.L., et al. Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. J Biol Chem 274 (1999) 3531-3540
8. Hotoda N., Koike H., Sasagawa N., and Ishiura S. A secreted form of human ADAM9 has an alpha-secretase activity for APP. Biochem Biophys Res Commun 293 (2002) 800-805
9. Fischer O.M., Hart S., Gschwind A., Prenzel N., and Ullrich A. Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol 24 (2004) 5172-5183
10. Higashiyama S., and Nanba D. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochim Biophys Acta 1751 (2005) 110-117
11. Hirao T., Nanba D., Tanaka M., et al. Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res 312 (2006) 331-339
12. Tanida S., Joh T., Itoh K., et al. The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells. Gastroenterology 127 (2004) 559-569
13. Shintani Y., Higashiyama S., Ohta M., et al. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res 64 (2004) 4190-4196
14. Mahimkar R.M., Visaya O., Pollock A.S., and Lovett D.H. The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins. Biochem J 385 (2005) 461-468
15. Kristiansen G., Pilarsky C., Wissmann C., et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 205 (2005) 359-376
16. Ohl F., Jung M., Xu C., et al. Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?. J Mol Med 83 (2005) 1014-1024
17. Grutzmann R., Luttges J., Sipos B., et al. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 90 (2004) 1053-1058
18. Karan D., Lin F.C., Bryan M., et al. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int J Oncol 23 (2003) 1365-1371
19. O'Shea C., McKie N., Buggy Y., et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 105 (2003) 754-761
20. Peduto L., Reuter V.E., Shaffer D.R., Scher H.I., and Blobel C.P. Critical function for ADAM9 in mouse prostate cancer. Cancer Res 65 (2005) 9312-9319
21. Sung S.Y., Kubo H., Shigemura K., et al. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res 66 (2006) 9519-9526
22. Carl-McGrath S., Lendeckel U., Ebert M., Roessner A., and Rocken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 26 (2005) 17-24
23. Le Pabic H., Bonnier D., Wewer U.M., et al. ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 37 (2003) 1056-1066
24. Grutzmann R., Foerder M., Alldinger I., et al. Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch 443 (2003) 508-517
25. Alldinger I., Dittert D., Peiper M., et al. Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer. Pancreatology 5 (2005) 370-379
26. Chin K., DeVries S., Fridlyand J., et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10 (2006) 529-541
27. Russ A.P., and Lampel S. The druggable genome: an update. Drug Discov Today 10 (2005) 1607-1610
28. Zigrino P., Mauch C., Fox J.W., and Nischt R. Adam-9 expression and regulation in human skin melanoma and melanoma cell lines. Int J Cancer 116 (2005) 853-859
29. Mazzocca A., Coppari R., De Franco R., et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res 65 (2005) 4728-4738
30. Shigemura K., Sung S.Y., Kubo H., et al. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate 67 (2007) 722-731